Dyadic Enters Commercial Agreement with Opes to Launch Recombinant Protein Products
Dyadic Applied BioSolutions has entered into a commercial agreement with Opes Diagnosticsto support the commercial launch of Dyadic's recombinant human transferrin, bovine transferrin, human FGF, and bovine FGF products for use in serum-free cell culture media applications in the life science, food and nutrition markets. Under the agreement, Opes will leverage its existing commercial relationships and market experience to identify and engage potential customers primarily in Europe, Israel, and Asia to accelerate market entry for Dyadic's recombinant protein portfolio in cell culture media and related applications, while Dyadic retains the ability to sell directly and to work with additional partners globally. The collaboration is intended to accelerate the penetration of Dyadic's recombinant protein products produced using its microbial expression platforms in industries including research, diagnostics, cultured meat and life sciences biomanufacturing that require reliable, scalable, and cost-effective sources of growth factors and functional proteins. Opes has already sampled multiple customers utilizing serum free cell culture media in life sciences, food and nutrition applications.
Trade with 70% Backtested Accuracy
Analyst Views on DYAI
About DYAI
About the author
Dyadic and Inzymes Advance Non-Animal Chymosin Commercialization
- Commercialization Milestone: Dyadic and Inzymes announced the planned commercialization of recombinant non-animal chymosin in 2026, marking the successful completion of final development activities under their 2023 collaboration agreement, earning a $200,000 milestone payment and enhancing the market potential for non-animal dairy enzymes.
- Market Potential: The global dairy processing enzyme market is estimated to reach $1.5 to $2.0 billion annually, driven by increasing cheese consumption and rising demand for sustainable fermentation-derived alternatives, positioning Dyadic's non-animal chymosin to meet this market need.
- Significant Technical Advantage: Dyadic's microbial expression platforms enable efficient development and scalable manufacturing, and when combined with Inzymes' commercialization expertise, ensure that the non-animal chymosin meets evolving customer requirements for performance, consistency, and supply reliability, enhancing market competitiveness.
- Portfolio Expansion: As additional non-animal dairy enzyme candidates progress, the collaboration between Dyadic and Inzymes will further enrich their product portfolio in the fermentation-derived food enzyme market, supporting diversified growth across life sciences, food and nutrition, and industrial biotechnology sectors.
Dyadic Launches AlbuFree™ DX Recombinant Human Albumin
- Product Launch: Dyadic and Proliant have launched AlbuFree™ DX recombinant human albumin, utilizing Dyadic's proprietary fungal expression technology, marking a significant advancement in Dyadic's commercialization strategy for recombinant protein products, which is expected to enhance the company's market share in the life sciences sector.
- Market Demand: The demand for recombinant human albumin is rising in cell culture and life science applications, and the introduction of AlbuFree™ DX not only meets the need for animal-free, scalable, and supply-secure inputs but also creates a recurring revenue stream for Dyadic.
- Collaborative Advantage: Proliant's extensive experience in global albumin production and distribution network will provide strong support for the market promotion of AlbuFree™ DX, ensuring product quality and reliability, thereby further solidifying Dyadic's market position.
- Future Outlook: Dyadic plans to continue advancing the development of additional recombinant proteins through a combination of internal programs and strategic partnerships, further expanding its product portfolio in life sciences, nutrition, and industrial applications, enhancing the company's long-term growth potential.
HC Wainwright & Co. Initiates Coverage on Dyadic International with a Buy Rating and Sets Price Target at $3
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
Dyadic to Showcase at Investor Conferences and BPI East
Company Overview: Dyadic International, Inc. is a biotechnology company focused on producing high-value proteins for life sciences, food, and industrial applications using proprietary gene expression platforms.
Upcoming Conferences: Joe Hazelton, President & COO of Dyadic, will present at several upcoming conferences, including the H.C. Wainwright 27th Annual Global Investment Conference and BioProcess International BPI East, to engage with investors and industry partners.
Dyadic International, Inc. (DYAI) Q2 2025 Earnings Call Transcript
Conference Call Overview: Dyadic International held its Q2 2025 earnings conference call on August 13, 2025, featuring key participants including President Joe Hazelton and CFO Ping Wang Rawson, who provided insights into the company's financial results and strategic direction.
Forward-Looking Statements: The call included forward-looking statements that carry risks and uncertainties, with a disclaimer from Dyadic regarding their obligation to update these projections.
Dyadic International Narrows Q2 Loss
Earnings Report and Strategic Shift: Dyadic International reported Q2 2025 earnings with a GAAP revenue of $967,000, marking a year-over-year increase. The company has undergone a rebranding to Dyadic Applied Biosolutions and shifted its focus from research to commercializing engineered protein platforms in life sciences and bioindustrial markets.
Financial Outlook and Cost Management: The company narrowed its net loss to $1.79 million while managing general and administrative costs effectively. Management anticipates additional revenues from product launches by late 2025 and aims to maintain operating expenses at or below prior-year levels.
Dyadic and Inzymes Advance Non-Animal Chymosin Commercialization
- Commercialization Milestone: Dyadic and Inzymes announced the planned commercialization of recombinant non-animal chymosin in 2026, marking the successful completion of final development activities under their 2023 collaboration agreement, earning a $200,000 milestone payment and enhancing the market potential for non-animal dairy enzymes.
- Market Potential: The global dairy processing enzyme market is estimated to reach $1.5 to $2.0 billion annually, driven by increasing cheese consumption and rising demand for sustainable fermentation-derived alternatives, positioning Dyadic's non-animal chymosin to meet this market need.
- Significant Technical Advantage: Dyadic's microbial expression platforms enable efficient development and scalable manufacturing, and when combined with Inzymes' commercialization expertise, ensure that the non-animal chymosin meets evolving customer requirements for performance, consistency, and supply reliability, enhancing market competitiveness.
- Portfolio Expansion: As additional non-animal dairy enzyme candidates progress, the collaboration between Dyadic and Inzymes will further enrich their product portfolio in the fermentation-derived food enzyme market, supporting diversified growth across life sciences, food and nutrition, and industrial biotechnology sectors.
Dyadic Launches AlbuFree™ DX Recombinant Human Albumin
- Product Launch: Dyadic and Proliant have launched AlbuFree™ DX recombinant human albumin, utilizing Dyadic's proprietary fungal expression technology, marking a significant advancement in Dyadic's commercialization strategy for recombinant protein products, which is expected to enhance the company's market share in the life sciences sector.
- Market Demand: The demand for recombinant human albumin is rising in cell culture and life science applications, and the introduction of AlbuFree™ DX not only meets the need for animal-free, scalable, and supply-secure inputs but also creates a recurring revenue stream for Dyadic.
- Collaborative Advantage: Proliant's extensive experience in global albumin production and distribution network will provide strong support for the market promotion of AlbuFree™ DX, ensuring product quality and reliability, thereby further solidifying Dyadic's market position.
- Future Outlook: Dyadic plans to continue advancing the development of additional recombinant proteins through a combination of internal programs and strategic partnerships, further expanding its product portfolio in life sciences, nutrition, and industrial applications, enhancing the company's long-term growth potential.
HC Wainwright & Co. Initiates Coverage on Dyadic International with a Buy Rating and Sets Price Target at $3
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
Dyadic to Showcase at Investor Conferences and BPI East
Company Overview: Dyadic International, Inc. is a biotechnology company focused on producing high-value proteins for life sciences, food, and industrial applications using proprietary gene expression platforms.
Upcoming Conferences: Joe Hazelton, President & COO of Dyadic, will present at several upcoming conferences, including the H.C. Wainwright 27th Annual Global Investment Conference and BioProcess International BPI East, to engage with investors and industry partners.
Dyadic International, Inc. (DYAI) Q2 2025 Earnings Call Transcript
Conference Call Overview: Dyadic International held its Q2 2025 earnings conference call on August 13, 2025, featuring key participants including President Joe Hazelton and CFO Ping Wang Rawson, who provided insights into the company's financial results and strategic direction.
Forward-Looking Statements: The call included forward-looking statements that carry risks and uncertainties, with a disclaimer from Dyadic regarding their obligation to update these projections.
Dyadic International Narrows Q2 Loss
Earnings Report and Strategic Shift: Dyadic International reported Q2 2025 earnings with a GAAP revenue of $967,000, marking a year-over-year increase. The company has undergone a rebranding to Dyadic Applied Biosolutions and shifted its focus from research to commercializing engineered protein platforms in life sciences and bioindustrial markets.
Financial Outlook and Cost Management: The company narrowed its net loss to $1.79 million while managing general and administrative costs effectively. Management anticipates additional revenues from product launches by late 2025 and aims to maintain operating expenses at or below prior-year levels.
